Society of Toxicologic
Pathology - India (STP-I)

Ninth Conference andContinuing Education Program on

Online Registration

Immuno-Oncology Therapeutics
and Toxicologic Pathology ofSpecial Sense Organs
27-29 October, 2023
Hotel Narayani Heights
Ahmedabad Airport-Gandhinagar Road,
Adjacent to Apollo Hospital, Bhat,
Gandhinagar, Gujarat- 382428, India

Venue
Hotel Narayani Heights

Pathologists

Poster sessions
featuring cuttingedge
research

Networking
opportunities

Award winning
opportunities

Exhibit halloffering
access toindustry
vendors

Few reasons to attend this conference
Scientific program featuring diverse range of sessions that are highly relevant to our day to day practice inindustry, covering topics such as:
Anatomy, physiology, immunology, and toxicologic pathology of tactile and gustatory sense organs inlaboratory animals
Ocular comparative anatomy in the preclinical setting
Ocular drug development
Safety and efficacy of Cancer Immunotherapies
NSG mouse models in immune-oncology therapeutics
Checkpoint inhibitors: biology, nonclinical and clinical safety
Immune-mediated adverse effects
Translatable efficacy and safety testing of mAb, Bispecific and CAR T therapies
SMAC mimetics and IL15-PD1-mediated toxicities in monkeys
Case studies
Peer review
OnlineRegistration fee before 10 Oct 2023
5000 INR: STP-I Members
6000 INR: Non-members
2000 INR: Students (Masters/PhD)

Registration fee between 11 Oct to 15 Oct 2023
6000 INR: STP-I Members
7000 INR: Non-members
3000 INR: Students (Masters/PhD)

OfflinePROGRAM OVERVIEW
Friday, 27 October, 2023 (Day 1)
Registration
Inauguration

07.30 am - 09.00 am
08.45 am - 09.30 am

Tracy Carlson

09.30 am - 10.45 am

Toxicologic pathology of the ear

Break10.45 am – 11.00 am

Ricardo de Miguel and Klaus Weber

11.00 am – 11.45 am

Tactile and gustatory sense organs in laboratory animals; anatomy
and toxicology

Christine Frieke Kuper

11.45 am - 12.30 pm

Anatomy and morphology of olfactory organ

Christine Frieke Kuper

12.30 pm - 01.15 pm

Histopathology of olfactory structures (INHAND diagnostic) andpossible consequences

Lunch

01.15 pm - 02.00 pm

Jacqueline Brassard

02.00 pm - 02.45 pm

Ocular comparative anatomy in preclinical setting

Meg Ferrell Ramos

02.45 pm - 03.30 pm

Ocular physiology and immunology: influences of ocular pathology

Break03.30 pm - 03.50 pm

Jacqueline Brassard

03.50 pm - 04.35 pm

Anterior segment pathology in the context of ocular drug development

Meg Ferrell Ramos

04.35 pm - 05.15 pm

Cultural event and dinner

07.00 pm - 10.00 pm

Posterior segment pathology: considerations in ocular drug
development

PROGRAM OVERVIEWSaturday, 28 October, 2023 (Day 2)
09.00 am - 09.45 am

Jagadeesh BayryAn insight on the basis for immunotherapy in cancer

Break09.45 am – 10.00 am

Charu Gupta

10.00 am – 10.45 am

Comparing humanized NSG mouse models to characterize andvalidate immuno-oncology therapeutics

Dharani K. Ajithdoss

10.45 am - 11.30 pm

Anticancer Innovation: Empowering T Cells

Nagaraja Muniappa

11.30 pm - 12.15 pm

Checkpoint inhibitors: biology, nonclinical and clinical safety

Florian Colbatzky

12.15 pm – 1.00 pm

SMAC mimetics

Lunch and poster evaluation

01.00 pm - 02.00 pm

Young scientist poster presentation 02.00 pm - 02.45 pm
Kiran Palyada

02.45 pm - 03.30 pm

IL15-PD1-mediated toxicities in monkeys

Break03.30 pm - 03.50 pm

Florian Colbatzky

03.50 pm - 04.35 pm

Immune-mediated adverse effects
Award ceremony (young scientist poster,
STP-I best poster and IATP Capen award) 04.35 pm - 05.15 pm
and group photograph

STP-I General body meeting

05.30 pm - 06.30 pm

Dinner

07.30 pm - 10.00 pm

PROGRAM OVERVIEW
Sunday, 29 October, 2023 (Day 3)
Tijo Thomas

09.00 am - 09.45 am

Validating a whole slide image management system on a GLPcompliant safety study

Klaus Weber

09.45 am – 10.30 am

Break

10.30 am – 10.45 am

Aaron Sargeant

10.45 am – 11.10 pm

Aaron Sargeant

11.10 am – 11.35 pm

Shambhunath Choudhary

11.35 am – 12.00 pm

Klaus Weber

12.00 pm – 12.30 pm

The impact of artefacts on study outcomes; examples of peer
reviews, pathology working groups and expert panels

Case study: Pathologist points to consider when recording findings incarcinogenicity studies, with emphasis on the hematopoietic system

Case study: The use of error-corrected DNA sequencing to detect
carcinogenic processes in Tg.RasH2 mice after three months of exposure
to genotoxic and non-genotoxic carcinogens

Case study: mRNA vaccines: efficacy and toxicity in preclinicalanimal models

Case study: Vascular leakage with IL-2 agonists

Charu Gupta

12.30 pm - 01.15 pm

Translatable efficacy and safety testing of mAb, Bispecific, andCAR T therapies

Venkatesha Udupa

01.15 pm – 01.30 pm

Concluding remarks

Lunch and departure

01.30 pm - 02.30 pm

AWARDS AND POSTERS
Young Scientist Poster Award

IATP Charles Capen Trainee Award

Professor M. K Shingatgeri Memorial Young Scientist
Poster Award is instituted by Dr. Vyas M Shingatgeri,
Dean at School of Biosciences, Apeejay Stya
University, Gurugram, Hariyana, in memory of Late
Professor M. K Shingatgeri, Former Dean of Bombay
Veterinary College and Professor and Head of its
Department of Pharmacology and Toxicology. The
award is restricted to the subject of Toxicologic
Pathology only. The Poster presentation should beoriginal work and should include title, authors,
address, purpose of study, methods, results andconclusions. The name of the presenting author
should be underlined.

The Charles Capen Trainee Award given by theInternational Academy of Toxicologic Pathology(IATP) recognizes Dr. Charles Capen and his legacy
as a researcher, teacher, and mentor to thepathology and toxicology communities spanningmore than four decades. Dr. Capen was recognizedworldwide as an exceptional leader in veterinary
and biomedical research. He was a highly regarded
mentor to numerous graduate students andpostdoctoral scientists. His students and trainees
are now leaders through out academia, government
and industry. The Charles Capen Awards provides
classic reference book to the awardee to further hisor her training and education in the field of
toxicologic pathology.

STP-I Best Poster Award
The abstract of poster presentation of about
250 words should include title, authors,
address, purpose of study, methods, results
and conclusions. The name of the presenting
author should be underlined.

The successful applicant must be a pathology,
toxicology or toxicologic pathology trainee. A
trainee is defined as an individual working on an
academic degree, in a training or residency
program, or in a postdoctoral training position andhave demonstrated achievements in the field of
toxicologic pathology including but not limited to:
Research contributing to public safety as it
relatesto the adverse health effects ofxenobiotics;
Establishing test methods and standards thatenhance the field of toxicologic pathology;
and/orDeveloping new or novel uses of toxicologic
pathology in safety research.
Suggested criteria for the selection of the award
recipient will be on poster presentations.
The IATP will present the recipient with an award
certificate and 300 USD or equivalent amount in
INR. A Fellow of the IATP or an eminent pathologist
will present the award certificate and money at the
STP-I meeting awards ceremony.

Abstract with email address should be submitted preferably through E-mail (not as an
attachment file but as a body of the mail) to the organizing secretary Dr. Praful Patel(E-mail: stpi.india@gmail.com) latest by 10 October 2023. Poster shall be of size 48
inches (Width) x 36 inches (Height). General template given may be followed.

SPEAKERS
Tracy Carlson, DVM, PhD, DACVPDr. Carlson received her DVM at North Carolina State University in2004 and subsequent PhD in innate immunity/tuberculosis andanatomic pathology residency training at the Ohio State University
through 2011. She currently works as a Senior Veterinary Pathologist
at Greenfield Pathology Services continuing her career as a medical
device and general toxicologic pathologist at Baxter Healthcare Inc,
MPI, and Charles River Laboratories. She has been supporting otic
histopathology since 2015 providing pathology support and study
histopathology evaluations at both MPI and Charles River
Laboratories. She is the current chair of the Education Committee for
the Society of Toxicologic Pathology and an active member of theSpecial Interest Groups for the special senses and medical devices.
Dr. Carlson has multiple publications including two book chapterson otic pathology currently in progress. She was an invited speakeron pathology of the middle ear for the modular course of the Special
Senses for the Society of Toxicologic Pathology in 2019.

Ricardo de Miguel, PhD, Dipl. ECVP
Ricardo graduated as DVM by the University of Zaragoza and lateras
MSc (Research) by the University of León. He is PhD in Animal Healthand board-certified diplomate of the European College of
Veterinary Pathologists (ECVP). He started working for AnaPath
Research SAU, an in vivo test facility located in Barcelona (Spain),
before moving to AnaPath Services GmbH (Switzerland) to further
develop his career as toxicologic pathologist. Experienced
investigative pathologist with more than 20 scientific publications
and fellowships in the United States, Uruguay, France, and Spain.
Deep interest in immunology, immunotoxicology, vaccinology,
neuropathology, ocular pathology, special technologies, andmedical device.

Christine Frieke Kuper, DVM, PhD, DACVP
Dr. Kuper is a board-certified toxicologic pathologist with extended
expertise in respiratory toxicity and immunopathology. She was aninvited contributor of workshops at ECVAM and in the US, and amember of working groups like OECD inhalation guidelines, NIEHS,
and INHAND harmonization of pathologic nomenclature. Her
research on immunopathology and respiratory toxicity included
histopathology as well as omics with low-molecular chemicalsensitizers. She worked at TNO, the Institution in the Netherlands forApplied Science, and at the RIVM, the Dutch Public Health Institute.
She received the BSTP Gopinath Lecture Award in 2016. She is now a
private consultant.

SPEAKERS
Jacqueline A. Brassard, DVM, MS, PhD, DACVP
Dr. Jacqueline Brassard received her D.V.M. degree Texas A&M
University (TAMU) in 1979 and practiced companion animal andexotic animal medicine for 3 years. In 1982, she returned to TAMU
and completed a combined anatomic and clinical residency inveterinary pathology in 1985 and an M.S. degree in Veterinary
Pathology in 1987. She continued her post-DVM pathology
education at Washington State University (WSU), where she passed
the ACVP certifying exam in 1988 and completed a Ph.D. degree in
Veterinary
andComparative
Anatomy,Physiology
andPharmacology in 1990. She then joined The Scripps ResearchInstitute (TSRI) in La Jolla, CA as a research associate in molecularhemostasis. In 1996, she began her career as a toxicologic
pathologist and worked for Searle, Monsanto, Pharmacia, Pfizer,
ICOS, and Allergan pharmaceutical companies before becoming a
toxicologic pathology consultant. She has co-authored journal
publications and book chapters in hemostasis, ocular drug
development, and gene therapy. She has presented on these same
topics for the American Society of Hematology, Society of
Toxicologic Pathology, and Society of Toxicology. As a member of
the Society of Toxicologic Pathology, she served/serves on multiple
INHAND Special Senses, including Rodent and Non-rodent Ocular
Working Groups and Non-Rodent Ocular Trimming and Sectioning
Working Group.

Meg Ferrell Ramos, DVM, PhD
Dr. Ramos received her DVM in 1986 from Washington State
University, and immediately moved to Hawaii where she spent six
years in small animal practice, followed by six years as a clinicalveterinarian at the Honolulu Zoo. She returned to academia taking afellowship at Johns Hopkins School of Medicine, completing her PhD
in Comparative Pathology at University of California, Davis in 2006.
Her career path shifted to pharma/biotech, with employment atAllergan and Regeneron, engaged primarily in ocular research anddrug development. She is currently employed as a Research Fellow
at AbbVie based in Irvine (formerly Allergan) supporting the ocularand large molecule immunology portfolio. Meg has co-authored
several manuscripts on ocular drug development and/or pathology
including five book chapters, chaired the rodent INHAND Special
Senses manuscript, and was guest editor for the STP Toxicologic
Pathology ocular edition, published 2021. She currently chairs thecommittee for INHAND Special Senses, and serves on the IQ
Ophthalmic Scoping Group.

SPEAKERS
Prof. Jagadeesh Bayry, BVSc, MVSc, PhD
Prof. Bayry is a graduate of Veterinary Medicine from Bengaluru(1996) with a specialization of Virology and Immunology from Indian
Veterinary Research Institute (1999). He received PhD in Immunology
from Sorbonne University, Paris in 2003 and following post-doctoral
research at University of Oxford, he joined Institut National de laSanté et de la Recherche Médicale (INSERM, The National Institute of
Health and Medical Research), Paris, France in 2006 as a faculty. In
2018, he became Director of Research at INSERM. In 2021, he joined IIT
Palakkad as a Professor of Biological Sciences and Engineering. His
research is aimed at fundamental Immunology, immunotherapy andhost-pathogen interaction. His h-index is 70 and he has authoredmore than 300 articles with over 17,000 citations. He has received
fellowship from the Academy of Translational Medicine Professionals(FAcadTM), Austria. Prof. Bayry serves as an Editor, Associate Editor
or Editorial Board member of various journals like Frontiers in
Immunology, Cellular & Molecular Immunology, Immunobiology,
Discovery Medicine, Scientific Reports, Immunotherapy, Antibodies,
PLoS ONE, Frontiers in Molecular Medicine, Virusdisease, and hasedited four books from Springer Publisher. He has also served as amember (2016-2022) of a commission 'LS6-Immunity, Infection and
Immunotherapy' at the European Research Council (ERC).

Charu Gupta, MTech, PhD
Dr. Charu Gupta earned her Ph.D. in molecular medicine from the
Hannover Medical School, Germany, where she gained mechanistic
and therapeutic insights into IDH1-mutated acute myeloblastic
leukemia. Her preclinical doctoral and postdoctoral work
contributed to the development of several AML pre-clinical models
and clinical trials. Her postdoctoral work at the University ofMichigan focused on identifying and characterizing adhesion
receptors required in neutrophil extravasation to better understandinflammation responses. Along with her research endeavors, Dr.
Gupta volunteers as a career podcast host with an online science
communication. As a Technical Information Scientist, Charuleverages her experience in mouse disease modeling, immunology,
hematology, and oncology to help further global scientificeducation, rigour and endeavors.

SPEAKERS
Dharani K. Ajithdoss, BVSc, MVSc, PhD, DACVP, DACVM
Dr. Dharani K. Ajithdoss currently holds the position of SeniorDirector of Pathology at Regeneron Pharmaceuticals Inc., New York,USA, where he provides toxicopathological support for the discovery
and development of drugs for a variety of human diseases,
including Ebola, COVID-19, atopic dermatitis, NASH, and prostatecancer, to name a few. He earned his veterinary medicine degreefrom Madras Veterinary College, Chennai, India, a graduate degreein microbiology from the College of Veterinary Sciences,
Hyderabad, India, and a doctorate degree in molecular virology
from Texas A&M University, Texas, USA. He then completed his
residency training in anatomic pathology at Texas A&M University.
Since 2012, he has been a diplomate of both the American College of
Veterinary Pathologists (ACVP) and the American College of
Veterinary Microbiologists (ACVM). He had previously been on thefaculty at Texas A&M University and Washington State University,where he taught veterinary students, trained pathology, andmicrobiology residents, provided pathology service, and conductedcollaborative research. At Regeneron, he evaluates the safety andefficacy of various therapeutic modalities, including bispecificmAbs, ADCs, AAVs, oncolytic viruses, siRNAs, and CRISPR/Cas9
sgRNAs in a variety of preclinical species. He has broad experiencein the pathological evaluation of several established and innovativerodent and nonhuman primate models of human diseases. He has
authored or co-authored several peer-reviewed publications inhigh-impact journals, including Science and Science Translational
Medicine, book chapters, regulatory documents, scientific posters,
and conference presentations. His leadership role includes directing
a pathology team, serving as discovery/digital pathology lead,providing training and mentorship for externs/interns, delivering
invited lectures, and serving on various committees of professionalsocieties, such as STP.

SPEAKERS
Nagaraja Muniappa, BVSc, MVSc, Ph.D, DACVP
Dr. Nagaraja Muniappa currently holds the position of the Compound
Leader/Project Team Member at Merck Inc., West Point, USA, where heprovides toxicopathological support for the discovery anddevelopment of drugs for a variety of human diseases, including
Ebola, COVID-19, atopic dermatitis, NASH, and prostate cancer, toname a few. He earned his Bachelors in Veterinary Sciences andMasters in Veterinary Medicine from Mysore Veterinary College,
Bangalore, India, and a doctorate degree in Veterinary Pathology
from University of Nebraska Medical Center, Lincoln, NE. He thencompleted his residency training in anatomic pathology at Michigan
State University, East Lansing, MI. Since 1999, he has been a Diplomateof American College of Veterinary Pathologists (ACVP).
He served as study pathologist and peer review pathologist for GLP
and non-GLP studies in various species and types including
carcinogenicity with small molecules, and variety of studies of
biologics (antibodies, therapeutic peptides, and vaccines). He wasinvolved in many collaborative research projects with SA Biomarker
group to identify and validate novel biomarkers of organ specifictoxicity. He has a broad experience in contributing 5 successful
NDA/MA and several Phase 1/2/3 candidates development. He also
served as safety assessment lead on number of external licensing
due diligence teams across Merck, which resulted in acquisition ofcompanies, or licensing of compounds for joint development. He helda Head of Discovery position at Hoffmann La-Roche.He has authoredor co-authored several peer-reviewed publications in high-impact
journals. He is a recipient of several awards viz., outstandingachievement Merck award, outstanding contribution to the nonclincal drug safety department at Haffmann-La Roche, center forbiotechnology fellowship at University of Nebraska and Maryland
biotechnology institute fellowship at university of Maryland.

Florian Colbatzky, DVM, PhD
Florian Colbatzky, DVM, PhD, Non-clinical Drug Safety-Germany,
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany,
started his professional career in academia at the University of
Veterinary Medicine in Hanover in 1986. In 1988, he moved to theInstitute of Veterinary Pathology, Ludwig-Maximilian-University,
Munich, where he stayed until the end of 1993, interrupted by a oneyear stay as visiting scientist at the Institute of Pathobiology,
Ontario Veterinary College, Guelph, Canada. Since the beginning of
1994, he has worked for BI since 1994 first leading various
laboratories (Molecular Pathology, Clinical Pathology, Electron
Microscopy), until he became Director Pathology in 2004. In 2019, he
was promoted to the position of a Scientific Director providing his
expertise within various developmental projects and sharing it withyounger colleagues. For many years, he was one of the organizers(and a regular speaker) of the annual seminars “Classicalexamples of toxicologic pathology” in Hanover.

SPEAKERS
Kiran Palyada, BVSc, MVSc, PhD, DACVP, DABTKiran Palyada is a diplomate of the American College of Veterinary
Pathologists (ACVP) with certification in anatomic pathology. He
did his BVSc in Bengaluru, Karnataka and MVSc (pathology) in
Hissar, Haryana. After obtaining his PhD in biomedical sciences at
Oklahoma State University, Stillwater, OK he pursued his residency
in pathology at Cornel University, Ithaca, NY. He has extensive
experience working as an anatomic pathologist in both CROs andpharmaceutical industries for over 15 years. He is also a diplomateof the American Board of Toxicology (ABT). He is currently working
at Pfizer based in San Diego, California. He is involved in the drug
safety evaluation of novel drug candidates (mostly oncology) inboth GLP and non-GLP environments. He is a program pathologist
for several projects at varying stages of development. He hassignificant experience in reading carcinogenicity studies andmodels of animal disease. He has an active interest in male
reproductive pathology.

Tijo Thomas
Tijo Thomas heads software development at AIRA MATRIX to deliver
pathology image analysis and management solutions. He has led
several software projects to completion in a career spanning over
20 years. He has contributed across portfolios such as program
management, product development and quality management. A
significant portion of his career – over 10 years - Tijo dealt withdigital pathology and AI-ML projects.
Tijo's projects are from multiple functional domains such as life
sciences, ERP, e-Governance, Document Management Systems andDigital Pathology. A certified Software Quality Analyst (by American
Society for Quality), Tijo has been part of many quality initiatives
including ISO 9001: 2000 and CMM L5 implementation during his
career.

SPEAKERS
Klaus Weber, DVM, PhD, MSBiol, DJSTP
Klaus Weber was born in East Germany and became a veterinarian
and a biologist. He was working in laboratories in East German andalso, for several years in human pathology. With over 25 years ofprofessional experience in human and animal pathology. Weber
was from 1991-2011 head of pathology at RCC/Harlan Laboratories.
Klaus Weber has experience in all laboratory species including fish
and invertebrates. His area of work covers short and long term as
well as oncogenicity studies with specialties in neuropathology,
inhalation pathology, bone marrow differentiation and various
other topics. His work resulted in numerous presentations andpublications. He founded in 2004 AnaPath GmbH in Switzerland, aholding covering nowadays ten independent pathologists. Aftertermination of his contract with Harlan Laboratories, he founded by
the end of 2012 a new company in Switzerland called AnaPath
Services GmbH, functionally active from spring 2013 onwards thatcovers with 32 technicians all subjects on the field of toxicologic
pathology including necropsy at client sites and histotechnique
including all specialties.

Aaron Sargeant, DVM, PhD, DACVP
Aaron Sargeant completed his DVM and PhD degrees and residency
training in veterinary anatomic pathology from The Ohio State
University in Columbus, Ohio. He began his career withcarcinogenicity studies at Battelle Memorial Institute in Columbus,
and for the last 13 years served as study pathologist for many
conventional 2-year bioassays in rodents as wells as 6-monthcarcinogenicity studies in the transgenic rasH2 model at Charles
River Laboratories (CRL) in Spencerville, Ohio. Most recently, he was a
global subject matter expert for carcinogenicity studies at CRL and
was the site head of pathology for the Spencerville CRL facility. In
2022, Aaron joined Janssen Pharmaceutical Companies of Johnson &Johnson as Scientific Director, Pathology, where he continues to be
involved with various carcinogenicity working groups and programs.
Aaron is an active member of the Society of Toxicologic Pathology,
where he will finish a term as Secretary-Treasurer in June 2023.

SPEAKERS
Shambhunath Choudhary, DVM, PhD, DACVP, DABTShambhu is a board-certified toxicologist, veterinary pathologist,
and a translational research scientist specialized in cancer biology
and vaccine research with organ system expertise innephrotoxicity, hepatotoxicity, and dermal toxicity. Dr. Choudharyobtained his DVM from Kerala Veterinary College in India, his PhD
and postdoctoral research trainings in cancer therapeutics from
University of Tennessee, and pathology residency from Kansas
State University (KSU). He worked at KSU as a comparative
pathologist and at Charles River Laboratories as a toxicologic
pathologist before joining Pfizer.
At Pfizer, Dr. Choudhary supports drug discovery and development
efforts at various research units and serves as a Pathology
Therapeutic Area Lead (PTAL) for Vaccine Research Unit in NY. He is
active in allied professional societies and has served as chair
and/or member on many committees, working groups, andscientific sessions. He has authored over 30 papers in peerreviewed international journals and is regularly invited to speak atinternational/national meetings and university seminars. He
serves as an editorial board member/reviewer for many
international journals and as a panelist for many fellowships,
grants, and awards.

INVITATION TO THE SPONSORS
Diamond Sponsors
Sponsorship amount: 350,000 INR
Booth (~200 sq ft) on all days of the conference
Free registrations: 4
Platinum Sponsors
Sponsorship amount: 200,000 INR
Booth (~150 sq ft) on all days of the conference
Free registrations: 3
Gold Sponsors
Sponsorship amount: 100,000 INR
Booth (~100 sq ft) on all days of the conference
Free registrations: 2

For Sponsorship, please contact Satish Panchal(satish.panchal@gmail.com)/9825319421
Deadline for Sponsorship: 10 October 2023

About Ahmedabad
The earliest settlements of the city were situated south of thecurrent old city and on the bank of Sabarmati river. It was known as
Ashaval or Ashapalli. In the 11th century, Karna of the Chaulukya
dynasty made the town his capital and named it Karnavati (Karna'stown). It was inscribed as the World Heritage City by UNESCO in
July 2017. The old city features rich wooden architecture, havelis,
khadkis, and pols. The wooden architecture is exemplary of theunique heritage and culture in Ahmedabad. It signifies contributions
to arts and crafts, traditions, and structure design, and is reflectiveof the city's occupants. The city's architecture was designed topromote a sense of community, family, and multiculturalism. This isevident in the city being home to institutions belonging to several
religions including Hinduism, Islam, Christianity, and Judaism.

Ahmedabad has emerged as an important economic
and industrial hub in India. It is the second-largest
producer of cotton in India, due to which it was known
as the 'Manchester of India' along with Kanpur. Cricket
is a popular sport in Ahmedabad; a newly built stadium,
called Narendra Modi Stadium at Motera canaccommodate 132,000 spectators, making it the largest
stadium in the world. Ahmedabad observes a range offestivals.

Celebrations and observances include Uttarayan, anannual kite-flying day on 14th and 15th January. Ninenights of Navratri are celebrated with people
performing Garba, the most popular folk dance ofGujarat, at venues across the city. The annual Rath
Yatra procession on the Ashadh-sud-bij date of the
Hindu calendar at the Jagannath Temple. Festivals
like Diwali, Holi, Christmas and Muharram (pan India
festivals) are also celebrated

Get ready to explore !
Akshardham Temple Gandhinagar

The term Akshardham means the divine abode of God andas the name specifies, Akshardham temple ofGandhinagar was built in honour of Swaminarayan by
BAPS Swaminarayan Sanstha. The best place to visit thathave its Pradarshini and first laser show.

Adalaj Step tell

The Adalaj stepwell or 'Vav', as it is called in Gujarati, is
intricately carved and is five stories deep. It was built in 1498.
An inscription in Sanskrit establishes the history of the
Adalaj stepwell found on a marble slab positioned in arecess on the first floor, from the eastern entry to the well.

Modhera sun temple

LothalAs one traverses the length and breadth of Gujarat, one
constantly stumbles across architectural legacies of the'Solanki' rule. You keep coming across living spaces andmonuments of another time, offering an eclectic glimpse of theartistic and ingenious beauty that makes this exotically statevibrant. A soothing drive amidst green farmlands almost 25 km
away from Mehsana on the way to the temples of goddess
Bahucharaji reposes the village of Modhera. Set along thebackdrop of River Pushpavati, surrounded by a terra-formed
garden of flowering trees and songs of birds, rests the famed Sun
temple of Modhera.

About 80km southwest of Ahmedabad, the city that stood atthis archaeological site 4500 years ago was one of the mostimportant of the Indus Valley civilisation, which extended
into what is now Pakistan. Excavations have revealed theworld’s oldest known artificial dock, which was connected toan old course of the Sabarmati River. Other features include
the acropolis, the lower town, the bead factory, thewarehouses, and the drainage system. The site has been
nominated to be enlisted as a UNESCO World Heritage Site.

Statue of Unity
The 182-metre (600 feet aprox.) tall statue has been built as an ode to theIron Man of India, Sardar Vallabhbhai Patel, the first home minister of
independent India. The colossal monument towers over River Narmada.
The Statue of Unity overlooks the vast surrounds and the river basin of theNarmada River and the sprawling Sardar Sarovar dam. It stands on the
Sadhu Bet hillock, connected by a 300-metre bridge, which offers accessfrom the mainland to the statue.
Contact for Tours and Travel Assistance
Akshar Tours & Travels: Harshil Barot, WhatsApp No. +91 98251 16560, email-domestic1@akshartours.com
Travel and Ease: Himanshu WhatsApp No. +91 98240 08686, email- Himanshu@TravelnEase.com

NARAYANIHEIGHTS
Email ID: info@narayaniheights.com
Phone No:+91 79 6170 1800

Hotels near by
Hotel Galaxy Inn

Hotel German Palace

Apricot Hotel

1.3 Km

1.6 Km

4.2 KmTribecca SelectHotel Kanan

Pristine Presidency

1.6 Km

1.9 Km

4.9 KmThe Ummed Ahmedabad
4.5 KmSTP-I Executive Committee

Venkatesha Udupa
MVSc, MSc (Tox), PhD,
ERT, DABT, DSP

President

Narendra Deshmukh
MVSc, DABTVice President

Prafulkumar Patel
MVSc, PhD, DIBTP
General Secretary

Satish Panchal
MVSc, DIBTP, DABT, ERTTreasurer

Sanjaykumar Paneliya
MVSc, PhD, DIBTP
MemberNikita Bhatt
MVSc, DIBTP
MemberMahesh Brahmankar
MVSc, DIBTP, DICVP
Member

www.toxpathindia.com
CEOConference Organizing Committee

Venkatesha Udupa
MVSc, MSc (Tox), PhD,
ERT, DABT, DSP

Narendra Deshmukh
MVSc, DABT

Prafulkumar Patel
MVSc, PhD, DIBTP

Satish Panchal
MVSc, DIBTP, DABT, ERT

Kamala Kannan
MVSc, DIBTP

Sanjaykumar Paneliya
MVSc, PhD, DIBTP

Nikita Bhatt
MVSc, DIBTP

Mahesh Brahmankar
MVSc, DIBTP, DICVP

Ashvin K Patel
MVSc, DIBTP

Bipin Trada
MVSc

Shekhar B. Kadam
MVSc, DIBTP, DABTSatishkumar Bhalodiya
MVSc, DIBTP, ERT, DABTVishal Patel
MVSc

Urvit Patel
MVSc

Pratik Panchal
MVSc

Kaushik Thakor
MVSc, PhD

Society of Toxicologic Pathology - India (STP-I)#29, 1st cross, Malleshwaram, Bangalore - 560 003, Karnataka, India
Email: stpi.india@gmail.com
www.toxpathindia.com